SMT201300065B - Formulazione farmaceutica comprendente uno o piu esteri di acido fumarico in una matrice erodibile - Google Patents

Formulazione farmaceutica comprendente uno o piu esteri di acido fumarico in una matrice erodibile

Info

Publication number
SMT201300065B
SMT201300065B SM201300065T SM201300065T SMT201300065B SM T201300065 B SMT201300065 B SM T201300065B SM 201300065 T SM201300065 T SM 201300065T SM 201300065 T SM201300065 T SM 201300065T SM T201300065 B SMT201300065 B SM T201300065B
Authority
SM
San Marino
Prior art keywords
acid esters
fumaric acid
pharmaceutical formulation
erodible matrix
erodible
Prior art date
Application number
SM201300065T
Other languages
English (en)
Italian (it)
Inventor
Roland Rupp
Henrik Nilsson
Original Assignee
Forward Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201300065(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forward Pharma As filed Critical Forward Pharma As
Publication of SMT201300065B publication Critical patent/SMT201300065B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201300065T 2009-01-09 2013-06-17 Formulazione farmaceutica comprendente uno o piu esteri di acido fumarico in una matrice erodibile SMT201300065B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14361309P 2009-01-09 2009-01-09
DKPA200900034 2009-01-09
PCT/EP2010/050172 WO2010079222A1 (en) 2009-01-09 2010-01-08 Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix

Publications (1)

Publication Number Publication Date
SMT201300065B true SMT201300065B (it) 2013-09-06

Family

ID=42026676

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300065T SMT201300065B (it) 2009-01-09 2013-06-17 Formulazione farmaceutica comprendente uno o piu esteri di acido fumarico in una matrice erodibile

Country Status (19)

Country Link
US (5) US8906420B2 (ko)
EP (4) EP3295936A1 (ko)
JP (3) JP5788331B2 (ko)
KR (1) KR101699912B1 (ko)
CN (2) CN109044985A (ko)
CY (2) CY1114010T1 (ko)
DK (2) DK2379063T4 (ko)
EA (1) EA201290596A1 (ko)
ES (2) ES2586761T3 (ko)
HK (1) HK1180943A1 (ko)
HR (2) HRP20130480T4 (ko)
HU (1) HUE030169T2 (ko)
PL (2) PL2564839T3 (ko)
PT (2) PT2564839T (ko)
RU (2) RU2552951C2 (ko)
SI (2) SI2379063T2 (ko)
SM (1) SMT201300065B (ko)
UA (3) UA125896C2 (ko)
WO (1) WO2010079222A1 (ko)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663197B1 (en) 2003-09-09 2007-12-05 Fumapharm AG The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
PL2801354T3 (pl) * 2004-10-08 2017-08-31 Forward Pharma A/S Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
WO2008096271A2 (en) * 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
EP3295936A1 (en) * 2009-01-09 2018-03-21 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
CN102427727A (zh) * 2009-04-29 2012-04-25 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
US9422226B2 (en) * 2011-06-08 2016-08-23 Biogen Ma Inc. Process for preparing high purity and crystalline dimethyl fumarate
EP2811994A4 (en) * 2012-02-07 2016-01-13 Biogen Ma Inc PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
US20140056973A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
CA2882713A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US20140275250A1 (en) * 2013-03-15 2014-09-18 Xenoport, Inc. Methods of Administering Monomethyl Fumarate
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
IL243660A0 (en) * 2013-08-26 2016-02-29 Fwp Ip Aps A pharmaceutical preparation containing dimethyl fumarate to be administered in a low daily dose
US20160206587A1 (en) * 2013-08-26 2016-07-21 Forward Pharma A/S Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
WO2015044853A2 (en) * 2013-09-25 2015-04-02 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of dimethyl fumarate
KR102335289B1 (ko) 2013-12-12 2021-12-06 알미랄, 에스.에이. 디메틸 푸마레이트를 포함하는 약학적 조성물
US10172794B2 (en) 2013-12-13 2019-01-08 Biogen Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
CN104288774B (zh) * 2014-04-21 2018-10-09 河南省健康伟业生物医药研究股份有限公司 一种肠溶包衣、富马酸二甲酯肠溶制剂及其制备方法
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
CN104523602B (zh) * 2014-12-12 2018-06-05 广东东阳光药业有限公司 一种富马酸二甲酯肠溶微片及其制备方法
EP3302461A4 (en) 2015-06-01 2019-02-13 Sun Pharmaceutical Industries Ltd PHARMACEUTICAL COMPOSITIONS OF DIMETHYLFUMARATE
MX2017016509A (es) 2015-06-17 2018-08-16 Biogen Ma Inc Particulas de dimetilfumarato y composiciones farmaceuticas de estas.
CN208077616U (zh) 2015-06-28 2018-11-09 S&S创新有限责任公司 一种用于接收并隔离非无菌计算机装置的柔性无菌外壳
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
RU2611415C1 (ru) * 2015-11-17 2017-02-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты)
AU2016383430B2 (en) * 2015-12-31 2022-08-04 Zaklady Farmaceutyczne Polpharma S.A. Enteric coated oral pharmaceutical preparation comprising dimethyl fumarate
CN108472260B (zh) * 2015-12-31 2021-08-10 波尔法玛制药工厂股份公司 用于制备包括富马酸二甲酯的肠溶包衣颗粒的方法
EP3407873A1 (en) * 2016-01-28 2018-12-05 Zaklady Farmaceutyczne Polpharma SA Process for preparation of a granulate comprising dimethyl fumarate
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
GR1009149B (el) * 2016-10-25 2017-10-31 Φαρματεν Αβεε Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων
WO2018234584A1 (en) 2017-06-23 2018-12-27 Almirall, S.A. PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
WO2020053219A1 (en) * 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
WO2020061636A1 (en) * 2018-09-28 2020-04-02 The University Of Adelaide Treatment of neuropathic pain
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153927A (en) 1966-08-25 1969-06-04 Wilhelm Hoerrmann Medicinal Composition Suitable For Treating Diseases Of The Retina
DE2703964A1 (de) 1975-07-08 1978-08-03 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2530372A1 (de) 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
US4145438A (en) 1975-09-10 1979-03-20 Fisons Limited Method for treatment of eczema or psoriasis
DE2621214C3 (de) 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE2840498C2 (de) 1978-09-18 1980-04-10 Walter Dr. 6700 Ludwigshafen Schweckendiek Pharmazeutische Zubereitungen zur Behandlung von Psoriasis
US4302440B1 (en) 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
CH664150A5 (de) 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US5149695A (en) 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
US4693896A (en) * 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
IL83775A (en) 1987-09-04 1991-12-15 Dexter Chemical Corp Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
US5242905A (en) 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US4965252A (en) 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
US5023245A (en) 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
US4911917A (en) 1988-06-28 1990-03-27 Hauser-Kuhrts, Inc. Cholesterol-lowering combination comopsitions of magnesium salt and niacin
DE3834794A1 (de) * 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
US5484610A (en) 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
PT621032E (pt) 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
FR2716965B1 (fr) 1994-03-02 1996-05-03 Matra Defense Engin largable à stabilisation et freinage aérodynamique.
US5589504A (en) 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
US5716625A (en) 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US6139850A (en) 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5804203A (en) 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
AU5787996A (en) 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
FR2749759B1 (fr) 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
EP0969869A2 (en) 1996-07-26 2000-01-12 Susan P. Perrine Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
US20050220909A1 (en) 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US20010024660A1 (en) * 1999-09-29 2001-09-27 Ismat Ullah Enteric coated pharmaceutical composition and method of manufacturing
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
IT1317042B1 (it) 2000-06-14 2003-05-26 Biosalts Srl Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono.
EP1172101A1 (en) 2000-06-20 2002-01-16 Helsinn Healthcare S.A. The use of nimesulide for the treatment of psoriasis and psoriatic arthritis
AU2001271824A1 (en) 2000-07-05 2002-01-14 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
EP1372634B1 (de) 2001-01-12 2009-11-11 Biogen Idec International GmbH Verwendung von fumarsäureamiden
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US7217431B2 (en) 2001-07-06 2007-05-15 Lifecycle Pharma A/S Controlled agglomeration
US20030044380A1 (en) 2001-07-19 2003-03-06 Zhu Yong Hua Adhesive including medicament
NO20014746D0 (no) 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
KR20050044459A (ko) 2001-11-13 2005-05-12 파마시아 코포레이션 파레콕시브 등의 설폰아미드 선구약물의 경구 투여 형태
US6613800B1 (en) 2001-12-03 2003-09-02 Steven A. Smith Method and compositions for treating psoriasis, eczema, seborrhea and arthritis
DE10214031A1 (de) 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
US6830759B2 (en) 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
ATE325115T1 (de) 2002-08-19 2006-06-15 Glaxo Group Ltd Pyrimidinderivate als selektive cox-2-inhibitoren
AU2003262060A1 (en) * 2002-09-10 2004-04-30 Taisho Pharmaceutical Co., Ltd. Solid preparation containing dioctyl sodium sulfosuccinate
MXPA04010956A (es) 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
CA2561082C (en) 2003-03-27 2014-07-15 Santosolve As Anti-inflammatory treatment based on strontium compounds
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
DK1622630T3 (da) 2003-05-07 2012-12-17 Osteologix As P009368epdk1
US20060216358A1 (en) 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
PL196544B1 (pl) 2003-08-08 2008-01-31 Biovail Lab Int Srl Tabletka o zmodyfikowanym uwalnianiu
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
EP1663197B1 (en) 2003-09-09 2007-12-05 Fumapharm AG The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
TW201240679A (en) 2004-03-12 2012-10-16 Capsugel Belgium Nv Pharmaceutical formulations
WO2005097082A1 (en) 2004-03-31 2005-10-20 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
TW200603792A (en) 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
CN1245873C (zh) 2004-08-21 2006-03-22 王立峰 富马酸二甲酯微胶囊及其制备方法
CN101056624A (zh) 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
PL2801354T3 (pl) * 2004-10-08 2017-08-31 Forward Pharma A/S Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
US20080004344A1 (en) 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1812374A1 (en) 2004-11-10 2007-08-01 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
US20080227847A1 (en) 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
ATE455783T1 (de) 2005-07-07 2010-02-15 Aditech Pharma Ag Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
WO2007012031A2 (en) 2005-07-19 2007-01-25 Precision Dynamics Corporation Semi-active rfid tag and related processes
JP2009510137A (ja) 2005-10-07 2009-03-12 アディテック・ファルマ・アクチボラゲット フマル酸エステルを含む制御放出医薬組成物
CN101304732A (zh) * 2005-10-07 2008-11-12 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
EP1940382A2 (en) 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
FR2894365B1 (fr) 2005-12-02 2008-01-11 Thales Sa Dispositif et procede de changement des zones prohibees a un aeronef
KR100917657B1 (ko) 2006-02-15 2009-09-18 주식회사 머젠스 산화환원 효소에 의해 ｎａｄ（ｐ）／ｎａｄ（ｐ）ｈ비율을 조절하는 방법
MX2008014059A (es) 2006-05-09 2008-11-14 Mallinckrodt Inc Formas de dosificacion solida de liberacion modificada en el orden de cero.
WO2007148744A1 (ja) 2006-06-21 2007-12-27 Santen Pharmaceutical Co., Ltd. フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤
WO2008096271A2 (en) 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
RS63489B1 (sr) 2007-02-08 2022-09-30 Biogen Ma Inc Kompozicije i upotrebe za tretiranje multiple skleroze
US20080274182A1 (en) 2007-05-03 2008-11-06 Regina Helena Alida Boekema Tablet coatings made from modified carboxymethylcellulose materials
KR20090028047A (ko) 2007-09-13 2009-03-18 경북대학교 산학협력단 디메틸푸마레이트의 신규 용도
CN101318901A (zh) 2008-06-17 2008-12-10 健雄职业技术学院 一种富马酸二甲酯的合成新工艺
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
US20120034274A1 (en) 2009-01-09 2012-02-09 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
EP3295936A1 (en) 2009-01-09 2018-03-21 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
CN101475477A (zh) 2009-01-23 2009-07-08 上海化学试剂研究所 反丁烯二酸二甲酯的制备方法
DK2414542T3 (da) 2009-03-30 2017-11-27 Tel Hashomer Medical Res Infrastructure & Services Ltd Fremgangsmåder til forudsigelse af klinisk forløb for og behandling af multipel sklerose
CN102427727A (zh) 2009-04-29 2012-04-25 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
CN101701943A (zh) 2009-11-05 2010-05-05 宁波中普检测技术服务有限公司 气相色谱-质谱联用测定产品中富马酸二甲酯的方法
HUE025878T2 (en) 2010-02-12 2016-05-30 Biogen Ma Inc Neuroprotection in demyelinating diseases

Also Published As

Publication number Publication date
EP2564839A2 (en) 2013-03-06
UA103844C2 (ru) 2013-11-25
JP2018138595A (ja) 2018-09-06
UA125896C2 (uk) 2022-07-06
SI2564839T1 (sl) 2016-09-30
EP2379063A1 (en) 2011-10-26
PL2564839T3 (pl) 2016-11-30
DK2379063T4 (da) 2021-05-25
EP2564839B1 (en) 2016-05-11
SI2379063T1 (sl) 2013-04-30
EP2564839A3 (en) 2013-04-17
RU2015113483A3 (ko) 2018-10-26
US20220079884A1 (en) 2022-03-17
KR20110116027A (ko) 2011-10-24
DK2564839T3 (en) 2016-07-25
JP2016006081A (ja) 2016-01-14
US8906420B2 (en) 2014-12-09
EP3090733A1 (en) 2016-11-09
EP2379063B1 (en) 2013-03-13
EP3295936A1 (en) 2018-03-21
CN109044985A (zh) 2018-12-21
HUE030169T2 (en) 2017-05-29
HRP20130480T1 (hr) 2013-06-30
DK2379063T3 (da) 2013-04-22
CY1117847T1 (el) 2017-05-17
HRP20130480T4 (hr) 2022-04-15
EP2379063B2 (en) 2021-02-24
RU2552951C2 (ru) 2015-06-10
PT2379063E (pt) 2013-05-03
HK1180943A1 (zh) 2013-11-01
KR101699912B1 (ko) 2017-01-25
SI2379063T2 (sl) 2021-09-30
JP5788331B2 (ja) 2015-09-30
ES2411972T5 (es) 2021-10-27
CN102369001A (zh) 2012-03-07
CY1114010T1 (el) 2016-07-27
WO2010079222A1 (en) 2010-07-15
PT2564839T (pt) 2016-07-14
RU2015113483A (ru) 2015-11-27
US20180221284A1 (en) 2018-08-09
US20190328675A1 (en) 2019-10-31
PL2379063T5 (pl) 2022-07-04
US20150272894A1 (en) 2015-10-01
US11173123B2 (en) 2021-11-16
RU2743637C2 (ru) 2021-02-20
JP6843798B2 (ja) 2021-03-17
UA112975C2 (uk) 2016-11-25
EA201290596A1 (ru) 2013-01-30
HRP20160982T1 (hr) 2016-11-04
PL2379063T3 (pl) 2013-08-30
ES2586761T3 (es) 2016-10-18
ES2411972T3 (es) 2013-07-09
US20120034303A1 (en) 2012-02-09
JP2012514624A (ja) 2012-06-28
RU2011128785A (ru) 2013-02-20

Similar Documents

Publication Publication Date Title
SMT201300065B (it) Formulazione farmaceutica comprendente uno o piu esteri di acido fumarico in una matrice erodibile
IL254839B (en) Derivatives of piperidine-4- and -2-carboxylic acids, perhydroazepine-4-carboxylic acid and (piperidin-4-yl)-acetic acid and pharmaceutical compositions comprising them
IL267556A (en) A pharmaceutical preparation containing recombinant hcg
SMT201400069B (it) Formulazione farmaceutica
GB0814931D0 (en) Active matrix display
GB0808178D0 (en) Active matrix displays
EP2562739A4 (en) ACTIVE MATRIX SUBSTRATE AND DISPLAY DEVICE
EP2477172A4 (en) ACTIVE MATRIX SUBSTRATE AND ACTIVE MATRIX DISPLAY DEVICE
BRPI0921654A2 (pt) formulação farmacêutica
EP2509061A4 (en) ACTIVE MATRIX SUBSTRATE AND DISPLAY DEVICE
EP2355083B8 (en) Scanning circuit for active matrix liquid crystal display
EP2398007A4 (en) DISPLAY DEVICE, METHOD FOR THE PRODUCTION THEREOF AND ACTIVE MATRIX SUBSTRATE
HK1252751A1 (zh) 包含溶蝕骨架中的一種或多種富馬酸酯的藥物製劑
EP2477171A4 (en) ACTIVE MATRIX SUBSTRATE AND DISPLAY DEVICE
DK2491021T3 (da) Nye acylpiperazinoner og deres anvendelse som lægemidler
BRPI1008983A2 (pt) formulação farmacêutica
ITRM20090203U1 (it) Dispositivo di stoccaggio ed erogazione per estensioni di capigliatura
TH0901004528A (th) สูตรผสมทางเภสัชกรรมที่ประกอบรวมด้วย4-[3-(4-ไซโคลโพรเพนคาร์บอนิล-พิเพอราซีน-1-คาร์บอนิล)-4-ฟลูออโร-เบนซิล]-2h-พธาลาซิน-1-โอนในสารกระจายของแข็ง
BRPI1005440A2 (pt) composição farmacêutica de matriz
TH135033B (th) เซลล์รีคอมบิแนนท์ซึ่งผลิต -อะมิโนคาร์บอกซิลิกแอสิด, -อะมิโนคาร์บอกซิลิกแอสิด เอสเทอร์หรือแลกแทมของพวกเขา